Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 1, 2014, Pages 46-54

  Li, Yan ^a   Liu, Lei ^a   Wang, Bin ^a   Wang, Jun ^a   Chen, Dongfeng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FATTY LIVER; FEMALE; FIBRINOGEN; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OMENTUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893917802     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.08.006     Document Type: Article

References (43)

1. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
2. Bhala N., Jouness R.I., Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013, 19:5169-5176.
3. Chitturi S., Wong V.W., Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011, 26:163-172.
4. Wong V.W. Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol 2013, 28:18-23.
5. Fan J.G., Farrell G.C. Epidemiology of Nonalcoholic fatty liver disease in China. J Hepatol 2009, 50:204-210.
6. Loria P., Lonardo A., Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013, 43:51-64.
7. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-50.
8. Musso G., Cassader M., De Michieli F., Rosina F., Orlandi F., Gambino R. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012, 56:933-942.
9. van der Poorten D., Milner K.L., Hui J., Hodge A., Trenell M.I., Kench J.G., et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008, 48:449-457.
10. Nguyen-Duy T.B., Nichaman M.Z., Church T.S., Blair S.N., Ross R. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003, 284:1065-1071.
11. Adiels M., Taskinen M.R., Packard C., Caslake M.J., Soro-Paavonen A., Westerbacka J., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755-765.
12. Targher G., Chonchol M., Miele L. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009, 35:277-287.
13. Targher G., Bertolini L., Rodella S., Lippi G., Franchini M., Zoppini G., et al. NASH predicts seruminflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008, 16:1394-1399.
14. Kuppan G., Anjana R.M., Deepa M., Paramasivam P., Chandrakumar S., Kaliyaperumal V., et al. Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians. Diabetes Technol Ther 2012, 14:152-158.
15. Coulon S., Francque S., Colle I., Verrijken A., Blomme B., Heindryckx F., et al. Evaluation of inflammatory and angiogenic factors in patients with Nonalcoholic fatty liver disease. Cytokine 2012, 59:442-449.
16. Fan J.G., Li F., Cai X.B., Peng Y.D., Ao Q.H., Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007, 22:1086-1091.
17. Purnak T., Purnak T., Efe C., Beyazit Y., Ozaslan E., Astan R., et al. Recent insights into the relationship between inflammatory liver diseases and atherosclerosis. J Investig Med 2011, 59:904-911.
18. Loria P., Lonardo A., Targher G. Is liver fat detrimental to vessels? Intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) 2008, 115:1-12.
19. The expert committee on the diagnosis and classification of diabetes mellitus Report of the expert committee on the diagnosis and classification of diabetes, mellitus. Diabetes Care 2003, 26(Suppl. 1):5-20.
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting serum glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
21. Petta S., Amato M., Cabibi D., Camma C., Pizzolanti G., Barcellona M.R., et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010, 52:543-552.
22. Brunt E.M., Janney C.G., Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
23. Speliotes E.K., Massaro J.M., Hoffmann U., Foster M.C., Sahani D.V., Hirschhorn J.N., et al. Liver fat is reproducibly measured using computed tomography in the Framingham Heart Study. J Gastroenterol Hepatol 2008, 23:894-899.
24. Boyce C.J., Pickhardt P.J., Kim D.H., Taylor A.J., Winter T.C., Bruce R.J., et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol 2010, 194:623-628.
25. Li Y., Hai J., Li L., et al. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine 2013, 43:376-386.
26. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
27. Low S., Chin M.C., Ma S., Heng D., Deurenberg M. Rationale for redefining obesity in Asians. Ann Acad Med Singapore 2009, 38:66-69.
28. Wang Z., Ma J., Si D. Optimal cut-off values and population means of waist circumference in different populations. Nutr Res Rev 2010, 23:191-199.
29. Fan J.G., Saibara T., Chitturi S., Kim B.I., Sung J.J., Chutaputti A. What are the risk factors and settings for Nonalcoholic fatty liver disease in Asia-Pacific?. J Gastroenterol Hepatol 2007, 22:794-800.
30. Despres J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444:881-887.
31. Amato M.C., Giordano C., Galia M. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010, 33:920-922.
32. Targher G., Bertolini L., Scala L., Zoppini G., Zenari L., Falezza G., et al. Nonalcoholic hepatic steatosis and its relation to increased serumbiomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005, 22:1354-1358.
33. Lonardo A., Sookoian S., Chonchol M., et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013, 19:5177-5192.
34. Sookoian S., Gianotti T.F., Rosselli M.S., Burgueno A.L., Castano G.O., Pirola C.J. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011, 218:378-385.
35. Lottati M., Kolka C.M., Stefanovski D. Greater omentectomy improves insulin sensitivity in nonobese dogs. Obesity (Silver Spring) 2009, 17:674-680.
36. Klein S. Is visceral fat responsible for the metabolic abnormalities associated with obesity? Implications of omentectomy. Diabetes Care 2010, 33:1693-1694.
37. Halperin F., Goldfine A.B. Metabolic surgery for type 2 diabetes: efficacy and risks. Curr Opin Endocrinol Diabetes Obes 2013, 20:98-105.
38. Kashyap S.R., Bhatt D.L., Wolski K., et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 2013, 36:2175-2182.
39. 2: an endocrinologist's perspective. Obes Surg 2013, 23:800-808.
40. Patel S.R., Hakim D., Mason J., Hakim N. The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes. Surg Obes Relat Dis 2013, 9:482-484.
41. Tilg H., Moschen A.R. Insulin resistance, inflammation, and Nonalcoholic fatty liver disease. Trends Endocrinol Metab 2008, 19:371-379.
42. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
43. Lonardo A., Loria P. If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?. Dig Liver Dis 2012, 44:451-452.